Suppr超能文献

利用抗Mi(MNS7)、Mur(MNS10)和MUT(MNS35)抗原的人单克隆抗体对台湾献血者中Mi抗原进行通用检测及血型糖蛋白杂交频率分析

Universal Detection of Mi Antigen and Frequencies of Glycophorin Hybrids among Blood Donors in Taiwan by Human Monoclonal Antibodies against Mi (MNS7), Mur (MNS10), and MUT (MNS35) Antigens.

作者信息

Yang Meng-Hua, Chen Jen-Wei, Sayaka Kaito, Uchikawa Makoto, Tsuno Nelson H, Wei Sheng-Tang, Hou Sheng-Mou, Chen Yann-Jang

机构信息

Head Office, Taiwan Blood Services Foundation, Taipei 10066, Taiwan.

Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.

出版信息

Diagnostics (Basel). 2021 Apr 29;11(5):806. doi: 10.3390/diagnostics11050806.

Abstract

Glycophorin hybrids such as GP.Mur are common in Southeast Asians. In Taiwan, clinically significant alloantibodies to the GP.Mur phenotype are the most important issue in blood banks. A large-scale screening of glycophorin hybrids in the Taiwanese population is urgently needed to ensure transfusion safety. Four clones of human hybridomas that secrete anti-Mi, anti-MUT, and anti-Mur were established by fusing human B-lymphocytes and myeloma cells (JMS-3). The specificity of each monoclonal antibody (MoAb) was characterized. Three MoAbs were applied on an Automated Pretransfusion Blood Testing Analyzer (PK7300/PK7400) for donor screening. Genotyping was performed to determine the detailed subgrouping of glycophorin hybrids. Four MoAbs are IgM antibodies. Anti-Mi (377T) binds to DXHKRDTYA, HKRDTYAAHT peptides, and anti-Mi (367T) binds to QTNDXHKRD peptides (X indicates T, M, or K). Anti-Mur is reactive with KRDTYPAHTA peptides. Anti-MUT is reactive with KHKRDTYA. A total of 78,327 donors were screened using three MoAbs, and 3690 (4.71%) were GP.Mur, 20 (0.025%) were GP.Hut, and 18 (0.022%) were GP.Vw. When the Mi antigen was introduced as routine screening, the frequency of Mi(a+) among blood donors in Taiwan was 4.66% (67,348/1,444,541). Mi antigen was implemented as a routine blood testing, and the results were labeled on all red blood cell (RBC) units.

摘要

诸如GP.Mur之类的血型糖蛋白杂合体在东南亚人群中很常见。在台湾,针对GP.Mur血型表型具有临床意义的同种抗体是血库中最重要的问题。迫切需要对台湾人群进行大规模的血型糖蛋白杂合体筛查,以确保输血安全。通过将人B淋巴细胞与骨髓瘤细胞(JMS-3)融合,建立了四个分泌抗-Mi、抗-MUT和抗-Mur的人杂交瘤克隆。对每种单克隆抗体(MoAb)的特异性进行了表征。三种MoAb应用于自动输血前血液检测分析仪(PK7300/PK7400)进行献血者筛查。进行基因分型以确定血型糖蛋白杂合体的详细亚群。四种MoAb均为IgM抗体。抗-Mi(377T)与DXHKRDTYA、HKRDTYAAHT肽结合,抗-Mi(367T)与QTNDXHKRD肽结合(X表示T、M或K)。抗-Mur与KRDTYPAHTA肽反应。抗-MUT与KHKRDTYA反应。使用三种MoAb对总共78327名献血者进行了筛查,其中3690名(4.71%)为GP.Mur,20名(0.025%)为GP.Hut,18名(0.022%)为GP.Vw。当将Mi抗原作为常规筛查项目时,台湾献血者中Mi(a+)的频率为4.66%(67348/1444541)。Mi抗原已作为常规血液检测项目实施,结果标注在所有红细胞(RBC)单位上。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验